Open Access
Vis Cancer Med
Volume 5, 2024
Article Number 5
Number of page(s) 5
Published online 10 June 2024
  1. Jaksa A, Louder A, Maksymiuk C, et al. A comparison of 7 oncology external control arm case studies: Critiques from regulatory and health technology assessment agencies. Value Health. 2022;25(12):1967–1976. [Google Scholar]
  2. Wang XM, Dormont F, Lorenzato C, et al. Current perspectives for external control arms in oncology clinical trials: Analysis of EMA approvals 2016–2021. J Cancer Policy. 2023;35:100403. [CrossRef] [PubMed] [Google Scholar]
  3. Lambert J, Lengline E, Porcher R, et al. Enriching single-arm clinical trials with external controls: Possibilities and pitfalls. Blood Adv. 2023;7(19):5680–5690. [CrossRef] [PubMed] [Google Scholar]
  4. FDA. Considerations for the design and conduct of externally controlled trials for drug and biological products guidance for industry. Available at: [Google Scholar]
  5. EMA. Reflection paper on establishing efficacy based on single-arm trials submitted as pivotal evidence in a marketing 6 authorisation: 7 Considerations on evidence from single-arm trials. Available at: [Google Scholar]
  6. Li P, Su Wang S, Chen YW, Use of real-world evidence for drug regulatory decisions in China: current status and future directions. Ther Innov Regul Sci. 2023;57(6):1167–1179. [Google Scholar]
  7. Neelapu SS, Locke FL, Bartlett N, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544. [CrossRef] [PubMed] [Google Scholar]
  8. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56. [CrossRef] [PubMed] [Google Scholar]
  9. Neelapu SS, Locke FL, Bartlett N, et al. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv. 2021;5(20):4149–4155. [CrossRef] [PubMed] [Google Scholar]
  10. Maziarz RT, Zhang J, Yang H, et al. Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2022;6(8):2536–2547. [CrossRef] [PubMed] [Google Scholar]
  11. Dimick JB, Ryan AM, Methods for evaluating changes in health care policy: The difference-in-differences approach. JAMA. 2014;312(22):2401–2402. [CrossRef] [PubMed] [Google Scholar]
  12. Bian J, Cristaldi KK, Summer AP, et al. Associations of a school-based, asthma-focused telehealth program with emergency department visits among children enrolled in South Carolina Medicaid. JAMA Pediatr. 2019;173(11):1041–1048. [CrossRef] [PubMed] [Google Scholar]
  13. Bian J, Chen B, Hershmen D, et al. Effects of FDA boxed warning of erythropoietin-stimulating agents on utilization and adverse outcome. J Clin Oncol. 2017;35(17):1945–1951. [CrossRef] [PubMed] [Google Scholar]
  14. Miller CJ, Smith SN, Pugatch M, Experimental and quasi-experimental designs in implementation research. Psychiatry Res. 2020;283:112452. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.